< Back to previous page
Organisation
Digestive Oncology
Division
Main organisation:Department of Oncology
Lifecycle:1 Aug 2022 → Today
Organisation profile:
Digestive Oncology
Keywords:oncology
Disciplines:Oncology
Current researchers
1 - 10 of 11 results
- Sabine Tejpar (Responsible)
- Sarah Cappuyns (Member)
- Jeroen Dekervel (Member)
- Ting Pu (Member)
- Sabine Tejpar (Member)
- Baki Topal (Member)
- Eric Van Cutsem (Member)
- Fausto Velez Bravo (Member)
- Sara Verbandt (Member)
- Chris Verslype (Member)
Projects
1 - 10 of 38
- Study the efficacy and mechanism of targeted TIM3 and VISTA in the treatment of gastroesophageal junction / gastric cancer patients with low immunogenicity and FLOT chemotherapy resistanceFrom14 Feb 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Using mucins as friends in colorectal cancer diagnostics and treatmentFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Obesity-associated Hepatocellular Carcinoma at Single Cell Resolution for Risk Prediction and Novel Therapeutics - HepatoSCRIPTFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Infrastructure for Targeted ProteomicsFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Unique IsoPlexis technology for multiplexed single cell functional profilingFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Modifying Outcomes of Metaplastic Oncogenesis of the ColonFrom1 Dec 2022 → TodayFunding: BOF - projects
- [18F]AlF-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors: comparison with [68Ga]Ga-DOTATATE and evaluation of routine clinical use.From3 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Querying and exploiting the spatial colorectal tumor ecosystem for novel biological, diagnostic and therapeutic insightsFrom1 Oct 2022 → TodayFunding: Fund Recuperation Fiscal Exemption
- Coevolution of epithelium in colorectal cancer: comprehensive characterization of progress-associated tumor heterogeneity in the colorectal cancerFrom1 Oct 2022 → TodayFunding: FWO junior postdoctoral fellowship
- Using mucins as friends in colorectal cancer diagnostics and treatmentFrom20 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 745
- A PHASE III STUDY COMPARING LAROTAXEL TO 5-FU (CONTINUOUS INTRAVENOUS 5-FU OR CAPECITABINE) IN PATIENTS WITH ADVANCED PANCREATIC CANCER (APC) PREVIOUSLY TREATED WITH A GEMCITABINE CONTAINING REGIMEN(2010)
Authors: Eric Van Cutsem
Pages: 12 - 13 - Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population(2015)
Authors: Eric Van Cutsem
Pages: 950 - 958 - Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer(2013)
Authors: Eric Van Cutsem
Pages: 493 - 502 - Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer(2013)
Authors: Eric Van Cutsem
Pages: 1735 - 1743 - Colon cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up(2008)
Authors: Eric Van Cutsem
Pages: 29 - 30 - DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype(2013)
Authors: Xavier Sagaert, Loredana Vecchione, Sabine Tejpar
Pages: 516 - 524 - Carcinoid heart disease: Case and literature review(2010)
Authors: Chris Verslype, Eric Van Cutsem, Bart Meuris, Paul Herijgers, Willem Flameng, Marie-Christine Herregods
Pages: 261 - 264 - The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer(2020)
Authors: Sabine Tejpar
Pages: 4313 - 4325 - Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group(2012)
Authors: Kathleen Lambein, Louis Libbrecht, Sabine Tejpar
Pages: 120 - 127 - Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study(2018)
Authors: Eric Van Cutsem
Pages: 602 - 609